Other uses of glucagon-like peptide-1 drugs GLP-1 receptor signaling is crucial in neuroinflammation and neurodegeneration after brain injuries, stroke, or neurodegenerative diseases.

FMP, the University of Oxford, and the University of Birmingham have developed a novel imaging approach to track how popular ...

Glucagon-like peptide-1 receptor (GLP-1R) agonists, originally developed for type 2 diabetes patients and popularized by their ability to rapidly reduce body weight in patients with obesity, have ...

Findings imply that Retatrutide's activation of the GLP-1 receptor might result in increased insulin release from pancreatic beta cells, similar to the natural hormone GLP-1.

About The Study: Between 2020 and 2023, the number of adolescents and young adults with glucagon-like peptide-1 receptor agonist (GLP-1RA) dispensing increased substantially. In contrast, the ...

Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular ...

DALLAS — Glucagon-like peptide-1 receptor agonists may reduce complications after total knee arthroplasty in patients with obesity but who are not diabetic, according to presented results ...

Cite this: Edited by Satish Kumar M. Risk for Ischemic Optic Neuropathy From Glucagon-Like Peptide 1 Receptor Agonists Too Rare to be Detected - Medscape - December 06, 2024.

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...

DALLAS — Results presented at the American Association of Hip and Knee Surgeons Annual Meeting showed 14 days may be the optimal cutoff time for glucagon-like peptide-1 receptor agonists prior ...